Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Clin Ther. 2015 May 29;37(6):1340–1351. doi: 10.1016/j.clinthera.2015.05.006

Table III.

Covariate screening during pharmacokinetic model development.

Covariate Minimum Objective Function Change in Minimum Objective Function P
Vd, L*
 Actual weight, kg (base model) 1751.044 – 0.028
 Body mass index, kg/m2 1750.359 −0.685 0.019
 Allometric weight, kg 1751.486 0.442 0.037
 Adjusted weight, kg 1751.667 0.623 0.041
 Body surface area, m2 1752.198 1.154 0.056
 Lean body mass, kg 1752.203 1.159 0.056
 Ideal weight, kg 1752.832 1.788 0.082
Clearance, L/h†
 Allometric weight, kg (final model) 1680.621 – 0.011
 Body surface area, m2 1676.776 −3.846 0.001
 Adjusted weight, kg 1680.388 −0.233 0.009
 Lean body mass, kg 1681.874 1.252 0.021
 Ideal weight, kg 1682.739 2.118 0.035
 Actual weight, kg 1682.968 2.348 0.041
 Body mass index, kg/m2 1685.685 5.064 0.224
*

The change in minimum objective function for the volume of distribution was calculated from the base model using actual weight.

†

Actual weight was the covariate for Vd used in all models to estimate clearance. The change in minimum objective function for clearance was calculated from the final model that incorporated the log function of age (in days) and serum creatinine (in milligrams per deciliter) as covariates along with different weights.